Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBITDA Margin (2023 - 2025)

Kura Oncology (KURA) has disclosed EBITDA Margin for 3 consecutive years, with 464.82% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 532066.0% to 464.82% in Q4 2025 year-over-year; TTM through Dec 2025 was 772.86%, a 1139349.0% decrease, with the full-year FY2025 number at 412.56%, down 9345.0% from a year prior.
  • EBITDA Margin was 464.82% for Q4 2025 at Kura Oncology, down from 385.53% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 16937.17% in Q1 2025 to a low of 464.82% in Q4 2025.
  • A 3-year average of 8741.31% and a median of 9431.52% in 2023 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 460803bps in 2025; the steepest drop was -1320713bps in 2025.
  • Kura Oncology's EBITDA Margin stood at 10284.77% in 2023, then crashed by -53bps to 4855.83% in 2024, then crashed by -110bps to 464.82% in 2025.
  • Per Business Quant, the three most recent readings for KURA's EBITDA Margin are 464.82% (Q4 2025), 385.53% (Q3 2025), and 16937.17% (Q1 2025).